CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-20). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 832 · Search date 2026-07-20 · Methodology v0.6

Alirocumab,
does it really help with Reduction of recurrent major cardiovascular events after a recent acute coronary syndrome?

30-Second Summary
B
Evidence Grade B · 78 · Safety unknown
Added to statins after a recent acute coronary syndrome, alirocumab reduces recurrent ischemic events, but absolute benefit depends on baseline risk
What the
research shows
Alirocumab is rated B because it reduces recurrent major cardiovascular events in patients with a recent acute coronary syndrome who remain above lipid thresholds despite high-intensity or maximally tolerated statin therapy. In the 18,924-participant ODYSSEY OUTCOMES trial, the composite of coronary death, nonfatal myocardial infarction, ischemic stroke, or hospitalization for unstable angina occurred in 9.5% versus 11.1%, with a hazard ratio of 0.85. The benefit extends beyond the LDL-C surrogate to direct clinical events, but the pivotal event evidence is concentrated in one large program funded by Sanofi and Regeneron, warranting B in parity with evolocumab.
What the
ads claim
Claims that lowering LDL completely prevents heart disease or that this is a cardiovascular injection for anyone without statins overreach. The established scope is add-on treatment for high-risk patients after a recent acute coronary syndrome whose lipids remain elevated despite appropriate statin therapy.
*

Useful facts when choosing a product

  • Praluent is a prescription subcutaneous injection, commonly given every two or four weeks with the regimen adjusted to the indication, LDL-C response, and product label.
  • The post-acute-coronary-syndrome event reduction was demonstrated as an addition to high-intensity or maximally tolerated statin therapy. Statin intolerance and other lipid-lowering combinations require individual assessment.
  • Cost, repeated self-injection, refrigeration, and insurance criteria affect persistence. Lower baseline LDL-C and absolute cardiovascular risk can mean a smaller absolute benefit.
  • Injection-site reactions were slightly more common than with placebo, while overall adverse events were generally similar. Hypersensitivity and lipid monitoring require separate management.
Gap Measurement · Verdict 832 · B 78
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Schwartz and colleagues randomized 18,924 patients one to 12 months after an acute coronary syndrome to alirocumab 75 mg or placebo every two weeks, with blinded dose adjustment targeting LDL-C of 25 to 50 mg/dL. Over a median 2.8 years, the primary composite occurred in 903 patients (9.5%) versus 1,052 (11.1%), hazard ratio 0.85 (95% CI 0.78 to 0.93). In the prespecified analysis by Szarek and colleagues, total nonfatal cardiovascular events including recurrences were reduced with a hazard ratio of 0.87 (95% CI 0.82 to 0.93). These analyses use the same large trial population and are not counted as two independent confirmatory trials.

02

Why this is classified as B (78)

In 18,924 ODYSSEY OUTCOMES participants, the direct ischemic-event composite fell from 11.1% to 9.5%, hazard ratio 0.85, and the total-events analysis was directionally consistent. This is large hard-endpoint evidence beyond a surrogate, but the pivotal evidence is concentrated in one jointly manufacturer-funded outcomes trial and the absolute difference is limited. In parity with evolocumab, this supports B with 78 points.

Counterpoint. For appropriately selected high-risk patients after a recent acute coronary syndrome whose lipids remain above threshold on statins, the modest absolute reduction can still be clinically meaningful.

Rejudgment record. New verdict — Prioritized the reduction in direct cardiovascular events in a randomized double-blind trial of 18,924 patients while accounting for concentration of pivotal confirmation in one Sanofi and Regeneron-funded outcomes program and applying parity with the B grade for evolocumab

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Reduction of recurrent major cardiovascular events after a recent acute coronary syndromeBA trial of 18,924 participants showed a significant reduction in direct ischemic events when added to statins.
LDL-C loweringAPCSK9 inhibition markedly lowers LDL-C, but the event verdict was not based on this surrogate alone.
Equal absolute benefit in every patientDAbsolute benefit varied with baseline LDL-C and cardiovascular risk and was greater at LDL-C of at least 100 mg/dL.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Schwartz GG et al. 2018, ODYSSEY OUTCOMESMulticenter randomized double-blind placebo-controlled cardiovascular outcomes trial18,924Sanofi and Regeneron PharmaceuticalsComposite of coronary death, nonfatal myocardial infarction, ischemic stroke, or hospitalization for unstable anginaOver a median 2.8 years, events fell from 11.1% to 9.5%, hazard ratio 0.85 (95% CI 0.78 to 0.93).Core large randomized trial with direct hard endpoints
Szarek M et al. 2019Prespecified total-events analysis of ODYSSEY OUTCOMES18,924Sanofi and Regeneron PharmaceuticalsTotal nonfatal cardiovascular events and deathTotal nonfatal cardiovascular events were reduced with a hazard ratio of 0.87 (95% CI 0.82 to 0.93).Consistency analysis for recurrences, not an independent trial
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-07-20).

Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107. PMID: 30403574. DOI: 10.1056/NEJMoa1801174.
checked
Szarek M, White HD, Schwartz GG, et al. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019;73(4):387-396. PMID: 30428396. DOI: 10.1016/j.jacc.2018.10.039.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-20 · Corrections: none

Cite this verdict

Alirocumab x reduction of recurrent major cardiovascular events after acute coronary syndrome Evidence Grade B card
[Chamgap] Alirocumab x reduction of recurrent major cardiovascular events after acute coronary syndrome — Evidence Grade B·78. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/alirocumab-recurrent-cardiovascular-events-after-acute-coronary-syndrome/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.